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A B S T R A C T
One means of combating the spread of human immunodeﬁciency virus (HIV) is through the delivery of long-
acting, antiretroviral (ARV) drugs for prevention and treatment. The development of a discreet, self-adminis-
tered and self-disabling delivery vehicle to deliver such ARV drugs could obviate compliance issues with daily
oral regimens. Alternatives in development, such as long-acting intramuscular (IM) injections, require regular
access to health care facilities and disposal facilities for sharps. Consequently, this proof of concept study was
developed to evaluate the use of dissolving microarray patches (MAPs) containing a long-acting (LA) nano-
suspension of the candidate ARV drug, rilpivirine (RPV). MAPs were mechanically strong and penetrated skin in
vitro, delivering RPV intradermally. In in vivo studies, the mean plasma concentration of RPV in rats (431 ng/ml
at the Day 7 time point) was approximately ten-fold greater than the trough concentration observed after a
single-dose in previous clinical studies. These results are the ﬁrst to indicate, by the determination of relative
exposures between IM and MAP administration, that larger multi-array dissolving MAPs could potentially be
used to eﬀectively deliver human doses of RPV LA. Importantly, RPV was also detected in the lymph nodes,
indicating the potential to deliver this ARV agent into one of the primary sites of HIV replication over extended
durations. These MAPs could potentially improve patient acceptability and adherence to HIV prevention and
treatment regimens and combat instances of needle-stick injury and the transmission of blood-borne diseases,
which would have far-reaching beneﬁts, particularly to those in the developing world.
1. Introduction
Antiretroviral (ARV) drugs have signiﬁcantly decreased human
immunodeﬁciency virus (HIV) and acquired immune deﬁciency syn-
drome (AIDS) related mortality and morbidity [1]. In high-income
countries, the life expectancy of people living with HIV/AIDS now ap-
proaches that of the HIV-negative population, but this is not the case in
sub-Saharan Africa, where AIDS is still the leading cause of mortality
among adults 15 to 59 years of age. Women are increasingly bearing a
disproportionate burden of the AIDS epidemic [2,3]. One means of
addressing this burden is through eﬀorts to develop long-acting ARV
drug delivery systems for HIV prevention that could be appropriate for
use by those at greatest risk of infection. Current guidelines for HIV
treatment recommend daily usage of oral ARV drugs but many patients
experience treatment fatigue, thus aﬀecting regimen adherence. The
development of long-acting (LA) ARV drugs and delivery systems pro-
mises to address and potentially combat these issues surrounding
treatment fatigue and poor adherence [4].
Rilpivirine (RPV) is a next-generation non-nucleoside reverse tran-
scriptase inhibitor (NNRTI) that exhibits potent activity against wild-
type HIV and some HIV mutants resistant to ﬁrst-generation NNRTIs
and has been approved for treatment since 2011 [5–7]. The standard
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adult oral dosage of RPV is a 25mg tablet, daily [5,8,9]. The physio-
chemical (Fig. 1A) and pharmacological properties of RPV have enabled
development of a long-acting RPV nanosuspension (RPV LA) by Janssen
Pharmaceutical, aimed at overcoming onerous daily oral dosing regi-
mens [10]. This innovative intramuscular (IM) RPV formulation re-
quires infrequent injections, at four or eight week intervals, is well
tolerated in animals and humans and elicits sustained drug concentra-
tions in systemic circulation [8]. The administration of RPV LA via the
IM route, however, requires administration by a trained health care
worker, which may limit access. Pain at the injection site has been
reported in clinical studies, which could impact acceptability of a future
product intended for use at either four or eight week intervals [7].
Misuse and inappropriate disposal of needles are also problems of
particular signiﬁcance in the developing world, potentially leading to
the transmission of blood-borne diseases. Recent studies carried out
over 6–12month periods assessing the frequency of needle-stick in-
juries in clinical settings have shown the prevalence of such injuries in
health care workers to be high over the speciﬁc reporting periods of the
studies: 51% in Benin City, Nigeria [11]; 52.7% in Asaba, Nigeria [12],
83.8% in Minna, Nigeria [13] and 86.1% in New Delhi, India [14]. Not
all needle-stick injuries are reported, with estimates suggesting that
between 40%–75% of such injuries are never reported [14].
The work presented here provides proof of principle for the use of
an alternative, needle-free delivery system for LA nanosuspensions in
the treatment of HIV, speciﬁcally focusing on determining the potential
to use novel dissolving microarray patch (MAP) technologies [15] to
facilitate intradermal delivery of RPV LA. MAPs are micron-scale de-
vices, which can painlessly pierce the outermost layer of the skin, the
stratum corneum, to facilitate intradermal delivery of drugs and vaccines
[16,17]. MAPs have never before been used to facilitate intradermal
delivery of LA nanosuspensions but their potential has previously been
lauded in the literature [18] and is represented schematically in Fig. 1B.
Infrequent application of MAPs could potentially obviate com-
pliance issues with conventional delivery strategies, such as daily oral
dosing regimens or IM injections, which require delivery by health care
providers. This approach indicates that RPV, delivered via MAP, could
be deposited as a depot into the skin and as the nanoparticles dissolve in
interstitial ﬂuid, the drug would slowly be released and absorbed into
the systemic circulation. If suﬃcient quantities of nanoparticles and
accordingly, RPV, can be deposited into the skin, then therapeutic
plasma levels of the drug could theoretically be maintained for pro-
longed periods [19–21]. Furthermore, work recently published by our
MAP research team indicated the potential for lymphatic uptake of a
nanoparticle-derived tracer dye, when delivered from dissolving MAPs
into the skin [17]. Sustained delivery of RPV with distribution to one of
the predominant sites of HIV replication, namely the secondary lymph
nodes, could have profound eﬀects on inhibition of HIV replication
[22]. With all of these considerations taken into account, it is antici-
pated that, in time, the development of an RPV LA MAP, importantly,
with the potential for self-administration, could expand access and
adherence to HIV treatment, particularly in low-resource settings and
could obviate requirements for the use of needles in drug administra-
tion.
2. Materials and methods
2.1. Materials
Poly(vinylpyrrolidone) (PVP) of molecular weight 360,000 Da; poly
(vinyl alcohol) (PVA) of molecular weight 9000–10,000 Da; poly
(ethylene glycol) (PEG) of varying molecular weights (200–600 Da) and
glycerol were all purchased from Sigma-Aldrich, Gillingham, Dorset,
UK. Gantrez™ S-97, copolymer of methyl vinyl ether and maleic acid
(PMVE/MA), with a molecular weight of 1500,000 Da was a gift from
Ashland, Kidderminster, UK. RPV base and long-acting RPV nanosus-
pension (RPV LA, 300mg/ml) were supplied by Janssen
Pharmaceutical, Beerse, Belgium. Biopsy punches were purchased from
Stiefel, Middlesex, UK and Tissue-Tek® optimal cutting temperature
medium was obtained from Sakura Thatcham, UK.
2.2. Preparation of PVA/RPV LA formulations for MAP casting
Low molecular PVA (MW 9000–10,000 Da) was used to formulate
the microneedles of the arrays and due to the low water solubility of
RPV, a long-acting RPV nanosuspension (RPV LA), developed and
supplied by Janssen Pharmaceutical, was the drug source used
throughout this work. MAPs were prepared using aqueous formulations
containing varying amounts of PVA and RPV LA. The formulations were
named according to their composition. For example, the 80R10P for-
mulation was cast with 80% (w/w) RPV LA and 10% (w/w) PVA, as
listed in Table 1. The process by which the MAPs were cast is depicted
schematically in Fig. 2A and B. Images of exemplar RPV LA MAPs are
presented in Fig. 2C.
The baseplate used in all of the documented studies was formulated
using aqueous solutions of 20% (w/w) PVP of molecular weight
360,000 Da and 1.5% (w/w) glycerol.
2.3. Fabrication process of two-layered dissolving RPV LA MAPs
Dissolving RPV LA MAPs with bioadhesive baseplates were pre-
pared in a two-step process of microneedle casting, followed by base-
plate adhesion behind the microneedles. The process is illustrated in
Fig. 2A. Brieﬂy, silicone MAP moulds were designed in the geometry:
14 microneedles× 14 microneedles with microneedle heights of
600 μm (the archetypal microneedle heights utilized in a vast range of
our previously published studies), base widths of 300 μm and inter-
spacing of 300 μm. MAPs were prepared by dispensing 150mg of
casting gel onto the top of the MAP moulds. A preformed, dry baseplate,
cast from an aqueous blend containing 20% (w/w) PVP and 1.5% (w/
Fig. 1. The chemical structure of RPV (A). Schematic representation of the
mode of RPV LA MAP application and subsequent in-skin dissolution of the RPV
LA MAP (B).
Table 1
Composition of the formulations used to prepare RPV LA MAPs.
Formulation Composition (%) (w/w)
RPV LA PVA Water
100R 100 0 0
80R10P 80 10 10
70R15P 70 15 15
60R20P 60 20 20
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w) glycerol, was then placed behind the microneedles. The moulds were
placed inside a positive pressure compression chamber and a pressure
of 3 bar was applied for 15min. Finally, the MAPs were dried at room
temperature for 24 h and were then removed from the moulds and used
in mechanical tests. The RPV LA containing formulation was distributed
between the needle tips and a thin baseplate behind the needles.
Diﬀerent formulations were prepared but it was established that the
optimum formulation was that containing 70% (w/w) RPV LA, 15% (w/
w) PVA and 15% (w/w) water (see results section). These MAPs were
produced containing a total of 30mg of RPV LA. The RPV LA loading in
the microneedles was calculated using Eq. 1, considering the pyramidal
geometry of the needle tips, the experimentally-determined density of
the RPV LA/PVA dry formulation and the calculated concentration of
RPV per mg of RPV LA/PVA dry formulation.
= ∙
∙ ∙ ∙RPV in the needle tips N h b ρ RPV( ) [ ]
3
2
(1)
where N is the number of microneedles per MAP; h and b are height and
base width of the microneedles (600 and 300 μm, respectively); ρ is the
density of the dry formulation and [RPV] is the concentration of RPV in
the dry formulation (expressed in mg RPV/mg material). To obtain the
density of the dry formulation, the following equation was used: ρ=w/
SX, where X is the mean thickness of the ﬁlm, S is the cross-sectional
area and w is the weight of the ﬁlm.
2.4. Determination of the insertion/mechanical capabilities of RPV LA
MAPs
The Paraﬁlm® skin simulant model was employed, as previously
described, as a means of determining the mechanical strength of the
RPV LA MAPs [23–25].
2.5. Evaluation of the eﬀect of PVA on NP size
The eﬀect of PVA on the NP size within the RPV LA was then
evaluated. A Nano ZS Zetasizer and DTS software (Malvern Instruments
Ltd., Worcestershire, UK), employed at a temperature of 25 °C, was used
in these experiments. Two samples, namely, RPV LA diluted in water
and RPV LA MAPs that were prepared, dried and then dissolved in
water were analysed.
2.6. Pharmaceutical analysis of RPV from ex vivo samples
RPV quantiﬁcation from excised neonatal porcine skin samples was
performed using a Phenomenex™ Luna 5 μm C18 [2] 100 Å column
(150× 4.6mm; Phenomenex, Cheshire, UK) held at 30 °C ± 5 °C and a
RP-HPLC (Waters Alliance HPLC System (e2695 separation module;
Waters Corporation, Milford, UK)) with UV detection at 282 nm. The
mobile phase was composed of 60:40; acetonitrile:water, with a ﬂow
rate of 1ml/min and a run time of 10min per sample. The injection
volume was 20 μl. The chromatograms obtained were analysed using
Waters Empower® 2 software. Least squares linear regression analysis
and correlation analysis were performed on the calibration curves
produced, enabling determination of the equation of the line, its coef-
ﬁcient of determination and the residual sum of squares (RSS). The
limits of detection (LOD) and quantiﬁcation (LOQ) for this method,
0.17 μg/ml and 0.55 μg/ml, respectively, were determined using an
approach based on the standard deviation of the response and the slope
of a representative calibration curve, according to the Q2(R1) guide-
lines from the International Conference on Harmonisation (ICH) [26].
RPV standards were prepared in mobile phase.
2.7. MAP in-skin dissolution
The dissolution rate of the RPV LA MAPs was investigated in excised
neonatal porcine skin. Skin samples were carefully shaved using a
disposable razor and then equilibrated in PBS (pH 7.4) before being
mounted onto a styrofoam block, coated with PBS-soaked absorbent
paper. MAPs were inserted into the skin with a pressure of 10 N/MAP
over 30 s using a TA.XTPlus Texture Analyser (Stable Micro Systems,
Surrey, UK) and the skin was then stored at 37 °C for the duration of the
experiment. MAPS were removed at designated time points and
Fig. 2. Schematic representation of the RPV LA MAP manufacturing process (A); micrographs of exemplar RPV LA MAPs generated (B) and digital images of RPV LA
MAPs (C).
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digitally imaged. Optical coherence tomography (OCT) (Michelson
Diagnostics Ltd., Kent, UK) was used to assess the successful insertion of
the MAPs into the excised skin, as reported previously [16,23].
2.8. Delivery of RPV LA into full-thickness porcine skin
Full-thickness skin, collected from stillborn piglets, was shaved
using a razor and then mounted onto a styrofoam block, coated with
PBS-soaked absorbent paper. RPV LA MAPs were inserted into the skin
using manual force, roughly equivalent to 20 N, over 30 s [23,24]. The
MAPs were maintained in place for 30, 60 or 120min and the samples
were incubated at 37 °C over the course of the experiment to mimic in
vivo conditions. Subsequently, the RPV LA MAPs were removed and a
tissue sample, taken from that portion of the skin where the RPV LA
MAP had been inserted, was obtained using a biopsy punch (6mm
diameter) (Stiefel, Middlesex, UK). A diagrammatic representation of
this procedure is presented in Fig. 5A. The samples were frozen,
mounted, ventral surface facing upwards, using optimal cutting tem-
perature medium (Sakura® Thatcham, UK) and cut into 50 μm sections
using a Leica CM1900 Cryostat (Leica Microsystems UK Ltd). To analyse
the amount of RPV LA that permeated into each slice, mobile phase was
added to tissue sections and these were vortexed for 20min to solubilise
the drug. Samples were then centrifuged at 14,000× g, 10min. Su-
pernatants were analysed using the validated HPLC methodology.
2.9. Pharmaceutical analysis of RPV from in vivo samples
RPV quantiﬁcation from rat plasma was performed using a
Phenomenex SphereClone 5 μm (150×4.60mm) column
(Phenomenex, Cheshire, UK) and a RP-HPLC (Agilent 1200® Binary
Pump, Agilent 1200® Standard Autosampler, Agilent 1200® Variable
Wavelength Detector, Agilent Technologies UK Ltd., Stockport, UK)
with UV detection at 282 nm. The mobile phase was composed of
65:35; acetonitrile (ACN):water containing 0.1% (v/v) triﬂuoroacetic
acid (≥ 99% pure TFA), with a ﬂow rate of 1ml/min, and a run time of
10min. The injection volume was 20 μl. The chromatograms obtained
were analysed using Agilent ChemStation® Software B.02.01. Least
squares linear regression analysis and correlation analysis were per-
formed on the calibration curves produced, enabling determination of
the equation of the line, its coeﬃcient of determination and the residual
sum of squares (RSS). The limits of detection (LOD) and quantiﬁcation
(LOQ) for this method were estimated according to the signal-to-noise
ratio guidelines outlined in the European Pharmacopoeia, version 8.0
[27]. LOD and LOQ ratios of 3:1 and 10:1, respectively, were used
throughout the analysis. RPV standards were spiked into blank rat
plasma and standards of 50 ng/ml met the LOQ of the system. For a
calculation of the mean plasma concentrations, samples below the LOQ
were treated as half the LOQ (i.e. 25 ng/ml).
2.10. Extraction of plasma and drug
The extraction of RPV from spiked, control plasma and test plasma
from rats in the MAP or IM cohorts was carried out as described pre-
viously [28–30].
2.11. In vivo studies
2.11.1. Application of RPV LA MAPs
Ethical permission for all in vivo experiments was obtained from the
Queen's University Belfast, Biological Services Unit (BSU) and all re-
searchers carrying out the work held Personal Licences from the UK
Home Oﬃce. Two cohorts were employed in in vivo studies: the in-
tradermal (MAP) cohort and the control IM (IM) cohort. Experiments
were conducted using female Sprague Dawley rats aged between 9 and
13 weeks upon commencement of the study and aged between 14 and
17 weeks upon completion of the study. Prior to the commencement of
experiments, rats were acclimatised to laboratory conditions for a 7-day
period. MAP applications were carried out as described previously and
MAPs were removed after 24 h [29]. An image of an exemplar MAP
post-application for 24 h is presented in Fig. 5A.
Those rats in the IM cohort received 60 μl of 30mg/ml RPV LA
(1.8mg dose) into the right hind thigh muscle.
2.11.2. Quantiﬁcation of RPV in blood and vaginal wash samples from
treated animals
Blood samples were collected from the treated rats, at pre-de-
termined time points (1, 4, 7, 28 and 56 days), into heparinised tubes
via the lateral tail vein. Plasma was separated from the whole blood and
prepared as described, prior to HPLC analysis.
Vaginal washes were collected by washing the vaginal cavity with
200 μl sterile water for injection (B. Braun Medical Ltd., Sheﬃeld, UK)
at pre-determined time points (1, 4, 7, 28 and 56 days). The samples
were centrifuged at 14,000× g for 10min at 4 °C to remove any debris.
A 35 μl volume of sample was then mixed with 65 μl acetonitrile (ACN),
and a sample of this was analysed by HPLC. For data analysis purposes,
arithmetic means were determined and plasma samples with RPV
concentrations below the LOQ of the system were included in data ta-
bles as half the LOQ, namely 25 ng/ml.
2.11.3. Quantiﬁcation of RPV in vaginal tissue and lymph nodes of treated
animals
Animals were culled at the pre-determined experimental endpoints
by CO2 overdose and vaginal tissue, axillary, iliac and external lumbar
lymph nodes were excised. The lymph nodes were weighed and then
homogenised at 50 Hz for 10min in a Qiagen TissueLyser LT (UK
Qiagen Ltd. Manchester, UK). Samples were centrifuged at 14,000× g
for 10min at 4 °C and supernatants were collected. The nodes were then
subjected to a second extraction procedure. Supernatants were dried
under a stream of nitrogen at 37 °C for 50min, samples were recon-
stituted in mobile phase and RPV content was quantiﬁed using the
validated HPLC methodology. Vaginal tissue was treated similarly;
however, the tissue was disrupted mechanically prior to homogenisa-
tion to increase the surface area in contact with the ACN, maximizing
drug recovery. The amount of RPV in the organs was expressed as ng of
drug per g of tissue (ng/g), in order to account for diﬀerences in tissue
masses between rats. For data analysis purposes, arithmetic means were
determined and plasma samples with RPV concentrations below the
LOQ of the system were included in data tables as half the LOQ, namely
25 ng/ml.
2.11.4. Estimation of human dose and patch size
Estimation of human dose for RPV LA MAP were conducted to
provide the same trough concentration as that observed after single-
dose RPV LA IM, 600mg, after 28 days (44 ng/ml), as this is the dosing
regimen and monthly therapeutic RPV LA IM regimen in clinical de-
velopment [29]. Given the current study evaluated single-dose RPV LA
MAP and RPV LA IM, the exposure achieved after single-dose admin-
istration of RPV LA IM in humans was selected rather than trough
concentrations achieved at steady-state. Using the mean concentration-
time data, the relative ratio of exposures after adjusting for diﬀerences
in doses administered between MAP and IM administration were esti-
mated. The relative ratio of exposures at the various time points after
dosing were utilized to estimate dose of RPV LA MAP needed to achieve
44 ng/ml using the human observed RPV LA IM data from Jackson
2014 as the comparator [29].
2.12. Statistical analysis
Data was analysed using the One-Way ANOVA parametric test,
followed by Tukey's multiple comparison post-hoc test. A p value<
0.05 was denoted as a signiﬁcant diﬀerence.
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3. Results and discussion
3.1. Preparation of various PVA/RPV LA formulations for MAP casting
MAPs were manufactured containing two layers. RPV LA was in-
corporated into the needle tips and into a thin ﬁlm behind the needles.
A rigid polymeric baseplate was added to facilitate insertion. Multiple
published studies have previously used multi-layered MAPs
[16,25,31–33]. The novelty of the present work was not the use of a
multi-layered MAP, but rather the exploratory nature of this approach
to evaluate the potential application of MAPs in delivery of long acting
formulations, and consequently to maximize the amount of RPV LA
administered. Previous studies have suggested that dissolving MAPs are
capable of delivering not only the cargo located in the needle tips but
also, in some instances, drug in the baseplate [29]. Consequently, these
MAPs contained a thin ﬁlm containing RPV LA formulation behind the
needle tips, to maximize the amount of formulation delivered.
MAPs were prepared using RPV LA formulated from aqueous blends
containing various PVA concentrations ranging from 0%–20% (w/w)
and baseplates cast from aqueous blends of 20% (w/w) poly(vi-
nylpyrrolidone) (PVP), 1.5% (w/w) glycerol. The Paraﬁlm® skin si-
mulant model was employed, as previously described, as a means of
determining the insertion ability of the RPV LA MAPs [23,24]. Upon
application of a pressure of 10 N/MAP over 30 s using a TA.XTPlus
Texture Analyser (Stable Micro Systems, Surrey, UK), the proﬁles of the
various MAPs indicated that they had suﬃcient mechanical strength to
successfully insert into the Paraﬁlm® multi-layered skin simulant
(Fig. 3A). Regardless of the formulation employed to cast the micro-
needles, the MAPs consistently pierced through two layers of Paraﬁlm®,
indicating constant and reproducible depths of insertion (Fig. 3A).
MAPs cast from aqueous blends containing<15% (w/w) PVA were
brittle, however, and some microneedles broke oﬀ the arrays upon in-
sertion, indicating a lack of mechanical strength.
3.2. Dissolving RPV LA MAP composition
The dissolving RPV LA MAPs were fabricated in two stages to avoid
drug wastage (Fig. 2). Following formulation optimisation studies, the
RPV LA MAPs used in all subsequent experiments were cast from
aqueous blends of 70R15P in the MAP and 20% (w/w) PVP, 1.5% (w/
w) glycerol in the baseplates. The MAPs were prepared as outlined
schematically in Fig. 2A. The actual loadings of RPV LA into the RPV LA
MAP equated to 30mg in patch, of which 2mg (1.9 ± 0.2mg) was in
the microneedles of the arrays.
3.3. Determination of the insertion/mechanical capabilities of RPV LA
MAPs
The percentage of holes created in Paraﬁlm® layers for the diﬀerent
dissolving MAP formulations tested is shown in Fig. 3A. The in vitro
insertion depths obtained for the four formulations displayed similar
trends and all were capable of piercing three layers of Paraﬁlm®. The
mean thickness of a Paraﬁlm® layer is 126 ± 7 μm [23], thus sug-
gesting that the MAPs inserted to depths of at least 378 μm of the total
600 μm height of the microneedles. The results generated in this study,
therefore, are consistent with work we have previously published using
a variety of other MAP formulations, where the insertion was estimated
to be approximately 60% of the total microneedle length [23,25]. MAPs
containing no PVA but rather 100% RPV LA, although able to penetrate
through the Paraﬁlm® layers, did not have suﬃcient mechanical
strength, as some of the microneedles broke away from the arrays and
lodged in the layers of Paraﬁlm®, as indicated in Fig. 3B. The MAPs
formulated with 70R15P showed superior mechanical stability com-
pared to the MAPs containing 10% (w/w) PVA and results indicated
that they could be inserted deeper into skin layers. Consequently, the
70R15P formulation was selected as the optimal formulation for MAP
preparation.
3.4. Evaluation of the eﬀect of PVA on NP size
The properties of the nanosuspension should not be modiﬁed after
being combined with PVA or dried to form the MAPs. Consequently, the
particle size was evaluated before and after the formulation process.
Even at the highest loading of PVA, there was no signiﬁcant eﬀect on
RPV nanoparticle size or polydispersity (Fig. 3C). It was apparent that
after formulating RPV LA in combination with PVA, the MAPs could be
easily dissolved in water and the RPV LA particle size distribution did
not change and continued to be monodisperse. Particle size distribution
is an important attribute for intradermal drug delivery [17]. Therefore,
it was crucial to ensure that the physicochemical properties of the na-
nosuspension did not change post-formulation. Importantly, the results
obtained here suggest that there was no signiﬁcant interaction between
the PVA and the RPV LA, thus suggesting that no modiﬁcation of the
particle occurred upon formulation and fabrication of the MAPs.
3.5. MAP in-skin dissolution
The dissolution of the needles of the RPV LA MAP in excised skin
occurred slowly, likely due to the high content of hydrophobic RPV LA
in the needles of the MAPs. The microscopic images presented in
Fig. 4A and B illustrates the dissolution of the needles. After 5 h, the
needles are no longer sharp and some have detached from the MAP,
remaining in situ in the skin. The pores created in the skin, 5 h post-MAP
application are clearly deﬁned in the OCT image presented in Fig. 4B.
Following removal of the RPV LA MAP from the skin at 24 h, RPV LA
deposits are clearly visible in the skin (Fig. 4C).
3.6. Delivery of RPV into full-thickness porcine skin
The results presented in Fig. 5 depict the amount of RPV, in relation
to skin depth, detected per mm3 of tissue, across three diﬀerent appli-
cation times, namely 30, 60 and 120min (Fig. 5A, B). The concentra-
tion of RPV in the tissue increased as a function of the application time
in the initial approximately 200 μm of tissue (Fig. 5B). The drug con-
centrations, in samples from the 30 and 60min application durations,
levelled oﬀ and remained relatively constant between approximately
200 and 600 μm, after which concentrations began to decrease. There
was more variation in the RPV concentrations detected in samples from
the 120min application. In all instances however, RPV was detected in
skin sections at depths> 600 μm, therefore deeper in the skin layers
than the heights of the MAPs themselves, indicating movement of the
drug in the tissue. Speciﬁcally, the total amounts of RPV detected in the
tissue sections at each of the time points were determined and are
presented in Fig. 5C. There is a marked increase in the RPV present in
the tissue after 120min. This increase is possibly due to the slow so-
lubilisation of the needles containing RPV LA. The diﬀusivity of nano-
particles is likely to be less than that of solubilised drug and, ad-
ditionally the hydrophobic nature of RPV LA would lead to slower
dissolution of the needles [34], as indicated by in-skin dissolution
studies.
3.7. Quantiﬁcation of RPV in plasma and vaginal wash samples from
treated animals
Female rats were treated with either an IM dose of RPV LA (1.8mg)
(four rats) or with simultaneous application of 4×MAPs (of which
2mg RPV LA/array was contained in the microneedles) (three rats). In
the MAP cohort, MAPs were applied to the backs of the rats and re-
moved after 24 h. It is evident from the exemplar digital image of a
single MAP post-removal (Fig. 6A) that not all MAPs dissolved over the
duration of application, which is not surprising as these MAPs have a
high content of poorly soluble particles. This ﬁnding is consistent with
M.T.C. Mc Crudden et al. Journal of Controlled Release 292 (2018) 119–129
123
the ex vivo results reported in the previous section. Accordingly, not all
drug encapsulated within the MAPs would be expected to be delivered
over the course of the 24 h application time, unlike the complete de-
livery from the IM injections. Importantly, there was no indication of
irritation on the skin of the rats following MAP application and re-
moval.
Plasma samples were collected from the animals after MAP and IM
administration and the mean concentrations of RPV in each cohort, at
Fig. 3. Insertion proﬁle of RPV LA MAPs containing diﬀerent amounts of PVA and RPV LA into a Paraﬁlm®multi-layered skin simulant, following the application of a
pressure of 10 N/MAP, (means ± SD, n=3) (A). Digital image of the ﬁrst layer of the skin simulant after the insertion of MAP formulated containing no PVA (B).
Size of RPV nanoparticles in nanosuspension (RPV Nanosusp) and RPV nanoparticles following MAP formulation with PVA, drying and then dissolution of the MAP in
water (RPV Nanosusp (40%)+PVA (30%)) (C).
Fig. 4. Representative digital micrographs illus-
trative of the dissolution of RPV LA MAP at speciﬁc
time points (0, 5 and 24 h) in excised neonatal por-
cine skin. Digital micrograph of a RPV LA MAP prior
to insertion into skin (A). Digital micrograph of a
RPV LA MAP upon removal from the skin after an
insertion time of 5 h and OCT image of the resulting
microconduits in the porcine skin following MAP
removal (B). Digital image and micrograph of por-
cine skin upon removal of RPV LA MAP post-24 h
insertion with RPV LA visible in the microconduits
which were created in the skin (C).
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sampling time points of 1, 4, 7, 28 and 56 days, are presented in
Figs. 6B and 7A, respectively. Those rats treated with RPV LA MAP
exhibited high RPV plasma concentrations at 1 and 7 days post-MAP
application (Table 2).
Speciﬁcally, the maximum mean plasma concentration of
547.5 ± 298.1 ng/ml was recorded just 1 day post-MAP application
with 430.7 ± 608.1 ng/ml detected after 7 days. At the Day 4 time
point, however, no samples within this cohort had RPV concentrations
above the limit of quantiﬁcation (LOQ) of the system. This was not
unexpected, however, as the RPV detected 1 day post-MAP application
would have consisted of rapidly dissolving RPV delivered intradermally
via MAP that had entered the systemic circulation. Four days post-MAP
application, encapsulated RPV could have accounted for the majority of
the drug in the animal and this would not have been quantiﬁable in the
plasma, as the drug would not yet have reached the systemic circula-
tion. Plasma concentrations of RPV subsequently decreased to
75.6 ± 71.5 ng/ml at 28 days and comparable RPV concentrations
were maintained up to the experimental endpoint of 56 days
(104.4 ± 51.9 ng/ml). Those rats treated with RPV LA via IM injection
exhibited lower initial RPV plasma concentrations. Following IM in-
jection, a peak concentration of 175.5 ± 197.6 ng/ml was detected
1 day post-injection and no samples had RPV concentrations above the
LOQ of the HPLC system at 7 days (25 ± 7.2 ng/ml). Interestingly, the
mean RPV plasma concentration at the experimental endpoint of
56 days (118.9 ± 54.2 ng/ml) was comparable to that achieved via
RPV LA MAP at the same time point (104.4 ± 51.9 ng/ml). In terms of
direct comparison of the results generated here with other experimental
studies, this is challenging, as stated previously, due to the fact that not
all of the drug encapsulated into the MAPs would eﬀectively be deliv-
ered in vivo. Some preclinical work carried out in 2010 studied the
pharmacokinetics, distribution and tolerability of RPV LA delivered via
IM injection in rats and dogs [35], although the RPV LA used in the
earlier work was of lower concentration (2.5%, compared to 30% in the
present study). In the 2010 study, the plasma concentrations of the drug
increased gradually up to 7 h post-dose and then declined, but remained
detectable up to 8 days post-dose, when 5mg/kg drug was adminis-
tered, and up to 42 days post-dose when 20mg/kg was administered.
For comparison, as the rats within the IM cohort of the study presented
here had a mean starting weight of 242 g, they therefore had the
equivalent of approximately 7mg/kg RPV LA administered. The MAP
cohort, with a mean starting weight of 248 g, had the equivalent of
approximately 32mg/kg RPV LA administered in the microneedles of
the arrays but again, not all of this would have been delivered.
Therefore, across the two studies (present study and the 2010 pre-
clinical study [35]), and considering the amount of drug administered,
rats treated via IM or MAP exhibited comparable patterns of sustained
drug in plasma over similar time frames. In the 2010 study, those rats
given 5mg/kg and 20mg/kg RPV LA had Cmax of 71 ng/ml and 158 ng/
ml, respectively at 7 h post-dose [35]. In the present study, mean
plasma concentrations of approximately 176 ng/ml (IM cohort) and
548 ng/ml (MAP cohort) were recorded at 24 h, but no blood samples
were collected earlier. The higher plasma concentrations of drug de-
tected in this study, and at a later time point, may be due to the in-
herent diﬀerences in the pharmacokinetic proﬁles for the drug, as de-
termined by the diﬀerences in RPV concentration between the two
formulations. As there are no previous studies that have delivered this
or any other LA nanosuspension drug in rats via MAP, the plasma
concentrations of drug post-MAP delivery of RPV LA must be con-
sidered in comparison to the IM control. In this regard, at 24 h, plasma
levels of the drug in the MAP cohort (547.5 ± 298.1 ng/ml) exceeded
Fig. 5. Insertion of RPV LA MAP into excised porcine skin, followed by deposition studies. RPV LA MAPs were inserted, for three diﬀerent durations (30, 60 or
120min), into excised full-thickness neonatal porcine skin, and following this, the deposition of drug into a biopsied piece of skin was determined. Schematic
representation of the experimental approach, indicating diﬀusion of drug into the excised skin (A). RPV concentrations (μg/mm3) in excised neonatal porcine skin
were determined, at the relevant time points, and as a function of the depth of the tissue sections. This experiment was carried out under temperature control at 37 °C,
(means ± SD, n=3) (B). The total amount of RPV (μg/mm3) in the biopsied tissue was expressed as a function of the application time (means ± SD, n= 3) (C).
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those of the IM cohort (175.5 ± 197.6 ng/ml). When the diﬀerences in
RPV LA dose administered are taken into consideration, this shows the
potential intradermal delivery capabilities of this nanosuspension drug
from MAPs. As stated earlier in the discussion, this assertion is further
backed up by the fact that the two delivery routes resulted in equivalent
mean plasma levels of the drug in rats at the experimental endpoint of
56 days.
There is currently no consensus therapeutic plasma concentration
for RPV but the documented drug plasma level above the protein-
binding adjusted concentration required to inhibit 90% of in vitro viral
replication (IC90) of 12.5 ng/ml has been suggested previously [5].
With this in mind, future studies must be carried out to optimise and
lower the LOQ, in order to improve the pharmacokinetic measure-
ments. As a precursor to this and using the data generated in this study,
and comparing to the plasma RPV levels determined by Jackson and
colleagues in a clinical pharmacokinetic study of IM RPV LA [28], we
can very cautiously predict the MAP patch size that may be necessary
for use in human studies. RPV LA has conventionally been administered
at monthly intervals via IM injection. Accordingly, convention dictates
that an optimised MAP would be anticipated to also deliver RPV LA for
28-day exposure. RPV LA IM at a dosing regimen of 600mg every
4 weeks is in Phase 3 clinical development for HIV prevention. The
2014 clinical study, carried out in HIV-negative volunteers, demon-
strated that 600mg IM dosing of RPV LA provided a mean plasma
concentration of 44.2 ng/ml, 28-days after single-dose administration
[28]. By evaluating the relative exposures between MAP and IM ad-
ministration and adjusting for diﬀerences in doses administered be-
tween the formulations used in this study, the prior published clinical
data was used to estimate the dose of RPV LA required for delivery by
MAP. Based upon the 28 day trough concentrations achieved after
single-dose administration of 600mg IM RPV LA, an RPV LA dose in the
RPV LA MAP of 1500mg, equating to a patch size of approximately
375 cm2, is estimated to be needed to achieve similar duration of ex-
posure after single-dose administration. A patch of this size would be
unrealistic and inappropriate for patient usage however. Theoretically,
an RPV LA MAP of approximately 28 cm2 could be cautiously predicted
to maintain therapeutic concentrations of RPV in plasma over 7 days in
humans, although further in vivo pharmacokinetic evaluations will now
have to be carried out to bolster this proof of concept data. A patch of
28 cm2 would actually be smaller than commercially available trans-
dermal patches including GlaxoSmithKline's (GSK) Nicotinell® nicotine
patches of 30 cm2 [36] and Janssen's Duragesic® CII (fentanyl) patches
of 32 and 42 cm2 [37]. In addition, a recent healthy volunteer study
demonstrated successful self-insertion of a 16 cm2 MAP, following ap-
propriate instruction, demonstrating clear feasibility of applying larger
MAP patches [38]. Important to consider is the empowerment such a
self-applied and discreet device would oﬀer to individuals, particularly
women, in the developing world who, instead of having to go to distant
health clinics once a month for LA injections, could apply MAPs at
home, thus limiting disruption to their family life and caring respon-
sibilities. Other medicines for chronic conditions are also given at 7-day
intervals, such as methotrexate for rheumatoid and juvenile arthritis.
The MAP microneedle lengths and densities can be increased with a
view to maximizing drug loading into the MAP, thus increasing plasma
concentrations and dosing intervals with RPV LA MAP. Future studies
are necessary to investigate this.
With reference to RPV in vaginal washes, no RPV was detected in
the vaginal washes collected from rats 7, 28 or 56 days after adminis-
tration of MAP or IM RPV LA. This is in contrast to clinical studies
where RPV concentrations in vaginal ﬂuid approximated those seen in
plasma [28]. This was potentially caused by low wash volumes or
limitations associated with analytical method sensitivity in our
Fig. 6. RPV quantiﬁcation in in vivo samples from animals treated with 4×RPV LA MAPs (4× 2mg RPV LA) (MAP cohort, three rats for each time point). An
exemplar MAP post-removal from a rat, indicating the extent of MAP dissolution over the course of the 24 h application period (A). Plasma levels of RPV at 1, 4, 7, 28
and 56 days post-MAP application, (means ± SD, n≥ 3 at each time point, in accordance with the experimental regime employed) (B). No plasma at the 4 day time
point had RPV levels above the LOQ of the system and so for analysis purposes, samples were treated as 25 ng/ml. Determination of the amount of RPV in excised
vaginal tissue, expressed as ng of drug per g of vaginal tissue (ng/g), (means ± SD, n=3; * P < 0.05; NS=not signiﬁcant) (C). Determination of the amount of
RPV in excised lymph nodes, expressed as ng of drug per g of lymph node tissue (ng/g) in animals treated for 7, 28 or 56 days, (means ± SD, n=3 in all cases;
NS=not signiﬁcant) (D). No axillary nodes at the 28-day time point or external lumbar nodes at the 56-day time point had RPV levels above the LOQ of the system.
For analysis purposes, these samples were all treated as 25 ng/ml and then adjusted for tissue mass.
M.T.C. Mc Crudden et al. Journal of Controlled Release 292 (2018) 119–129
126
Fi
g.
7.
R
PV
qu
an
ti
ﬁ
ca
ti
on
in
in
vi
vo
sa
m
pl
es
fr
om
an
im
al
s
tr
ea
te
d
w
it
h
R
PV
LA
vi
a
IM
in
je
ct
io
n
(1
.8
m
g)
(I
M
co
ho
rt
,f
ou
r
ra
ts
fo
r
ea
ch
ti
m
e
po
in
t)
.P
la
sm
a
le
ve
ls
of
R
PV
at
1,
4,
7,
28
an
d
56
da
ys
po
st
-I
M
in
je
ct
io
n
of
R
PV
,
(m
ea
ns
±
SD
,n
≥
4
at
ea
ch
ti
m
e
po
in
t,
in
ac
co
rd
an
ce
w
it
h
th
e
ex
pe
ri
m
en
ta
lr
eg
im
e
em
pl
oy
ed
)
(A
).
N
o
pl
as
m
a
at
th
e
7-
da
y
ti
m
e
po
in
th
ad
R
PV
le
ve
ls
ab
ov
e
th
e
LO
Q
of
th
e
sy
st
em
an
d
so
fo
r
an
al
ys
is
pu
rp
os
es
,s
am
pl
es
w
er
e
tr
ea
te
d
as
25
ng
/m
l.
D
et
er
m
in
at
io
n
of
th
e
am
ou
nt
of
R
PV
in
ex
ci
se
d
va
gi
na
lt
is
su
e,
ex
pr
es
se
d
as
ng
of
dr
ug
pe
r
g
of
va
gi
na
lt
is
su
e
(n
g/
g)
,(
m
ea
ns
±
SD
,n
=
4;
*
P
<
0.
05
;N
S
=
no
ts
ig
ni
ﬁ
ca
nt
)
(B
).
D
et
er
m
in
at
io
n
of
th
e
am
ou
nt
of
R
PV
in
ex
ci
se
d
ly
m
ph
no
de
s,
ex
pr
es
se
d
as
ng
of
dr
ug
pe
r
g
of
ly
m
ph
no
de
ti
ss
ue
(n
g/
g)
in
an
im
al
s
tr
ea
te
d
fo
r
7,
28
or
56
da
ys
,(
m
ea
ns
±
SD
,n
=
4
in
al
lc
as
es
;N
S
=
no
ts
ig
ni
ﬁ
ca
nt
)
(C
).
N
o
ly
m
ph
no
de
s
at
th
e
28
-d
ay
ti
m
e
po
in
t
ha
d
R
PV
le
ve
ls
ab
ov
e
th
e
LO
Q
of
th
e
sy
st
em
.F
or
an
al
ys
is
pu
rp
os
es
,t
he
se
sa
m
pl
es
w
er
e
al
l
tr
ea
te
d
as
25
ng
/m
l
an
d
th
en
ad
ju
st
ed
fo
r
ti
ss
ue
m
as
s.
M.T.C. Mc Crudden et al. Journal of Controlled Release 292 (2018) 119–129
127
preclinical studies.
3.8. Quantiﬁcation of RPV in vaginal tissue and lymph nodes of treated
animals
Vaginal tissue was extracted from all animals at the requisite ex-
perimental endpoints and RPV concentrations were expressed relative
to the mass of the tissue removed from each animal (ng/g tissue). In
animals treated with RPV LA MAP, RPV concentrations were highest in
animals culled 7 days post-MAP application (1238 ± 347 ng/g tissue)
(Fig. 6C) and decreased in rats culled 28 (549 ± 304 ng/g tissue) and
56 (169 ± 84 ng/g tissue) days post-MAP application (Fig. 6C), as
anticipated. RPV concentrations in extracted vaginal tissue from rats
culled at 7 and 56 days were signiﬁcantly diﬀerent (P=0.0273).
In animals treated with RPV LA IM injection, the RPV concentra-
tions in the vaginal tissue did not peak as high as those recorded in the
MAP study arm (Fig. 7B). RPV concentrations in the 7 and 28 day co-
horts were comparable at 633 ± 239 ng/g tissue and 800 ± 257 ng/g
tissue, respectively. The only signiﬁcant diﬀerence in RPV concentra-
tions in the vaginal tissue in this experimental cohort was between 28
and 56 days (P=0.0183). The concentrations in the 56-day IM cohort
(197 ± 120 ng/g tissue) were similar to those determined at the same
time point in the MAP study arm (169 ± 84 ng/g tissue). Once again,
these results show that RPV LA can be successfully delivered in-
tradermally via MAP. Interestingly, the localised tissue concentrations
of RPV, when delivered from dissolving MAPs, were comparable to
those reached via conventional IM delivery of the drug. The diﬀerences
in RPV concentrations in vaginal tissue across the two treatment groups
were also compared at each time point and there were no statistically
signiﬁcant diﬀerences between the treatment cohorts at common time
points.
Secondary lymph nodes are one of the principal sites of HIV re-
plication and the restricted penetration of ARV drugs into these re-
servoir compartments may be one of the main mechanisms of viral
persistence in individuals [22]. Consequently, delivery systems that can
target ARV drugs to these compartments are of particular interest and
importance. It has been postulated that intradermal injection may also
promote enhanced lymphatic uptake when compared to IM or sub-
cutaneous injection. This may be due to higher interstitial pressure and
lymph ﬂow rates in the skin relative to other interstitial sites [39].
Accordingly, lymph node–derived concentrations of RPV were also
determined in this study. Axillary lymph nodes were extracted as ex-
amples of somatic nodes, draining from the skin and underlying mus-
culature, while iliac and external lumbar nodes were extracted as ex-
amples of visceral nodes, which drain from the thoracic, abdominal and
pelvic organs. The concentrations of RPV in iliac, external lumbar and
axillary lymph nodes were then determined and expressed relative to
the mass of the tissue removed from each animal (ng/g tissue) (Figs. 6D
and 7C). Those rats with RPV levels below the LOQ of the system were
treated in data analysis as having RPV of 25 ng/ml, which was then
adjusted for the tissue mass of individual nodes.
In the MAP arm of the study, two out of three rats in the 7-day
cohort had quantiﬁable RPV in the iliac nodes, external lumbar nodes
and axillary nodes. In the 28- and 56-day cohorts, however, only the
iliac nodes had quantiﬁable RPV in all of the animals, with con-
centrations of 1106 ± 278 ng/g tissue and 679 ± 382 ng/g tissue for
the 28- and 56-day cohorts, respectively. RPV concentrations in the
axillary nodes at 28 days and the external lumbar nodes at 56 days were
all below the LOQ of the HPLC method. Irrespective of the cohort and as
such, the length of time post-RPV LA MAP application, RPV was con-
sistently found in the iliac nodes of all animals treated via these dis-
solving MAPs. The detection of RPV in lymph nodes over extended
periods draws a parallel with a recent study using a long-acting ARV
drug-combination which reported the same phenomenon [40]. In the
MAP arm of the present study, there were no signiﬁcant diﬀerences in
RPV concentrations in any of the lymph nodes across the diﬀerent time
points.
In contrast to the MAP study arm, after IM administration RPV was
not quantiﬁed in the iliac nodes of all of the animals employed in the
study. Rather, RPV concentrations were below the LOQ of the HPLC
system in the iliac nodes of all of the animals in the 28-day cohort, with
only one animal in the 56-day cohort having quantiﬁable RPV (Fig. 7C).
In contrast, three rats in the 7-day cohort had quantiﬁable RPV in iliac
nodes (639, 5423 and 20,620 ng/g). Interestingly, there was no sig-
niﬁcant diﬀerence between the RPV concentrations in iliac nodes across
the three diﬀerent time points. In all cases, RPV concentrations in iliac,
external lumbar and axillary nodes at the 28-day time point were below
the LOQ of the HPLC system. At 56 days, only one animal had quanti-
ﬁable RPV in the iliac node, while two animals had drug quantiﬁed in
the external lumbar node and similarly two had drug quantiﬁed in the
axillary nodes. Once again, in the IM study arm, there were no statis-
tical diﬀerences in RPV concentrations in any of the lymph nodes across
the diﬀerent time points tested. There were also no statistical diﬀer-
ences in RPV concentrations across common lymph nodes in the two
study arms. In the only equivalent study carried out in rats, in which
male rats received either 5 or 20mg/kg RPV LA via IM, no drug was
detectable in lymphoid tissues (thymus or spleen) of the rats 8 weeks
post-dose [35]. No lymph nodes were extracted from the animals used
in that study however. In a parallel study in beagle dogs, RPV was
detected, ranging between 6 and 19 ng/mg in lymph nodes, 1 month
post-IM dose of RPV LA [35]. The results presented here may be con-
sidered comparable to those reported previously but using a novel de-
livery vehicle. Importantly, as there were no signiﬁcant diﬀerences in
the levels of drug in the iliac nodes across various time points, this
suggests the drug exposure is sustained, at least up to 8 weeks post-
administration in those nodes.
In considering the possibility for self-application of MAPs, our re-
search team and others have already published user feasibility studies,
with results indicating that MAPs can be reproducibly applied to the
skin without the need for complex applicators or specialist personnel
[41–43]. In addition to this, recent work from our laboratory has de-
duced that larger, multi-array patches (16 cm2 MAPs) can be success-
fully self-administered by individuals, and to comparable depths as
smaller patches with a single array, following appropriate instruction
Table 2
Mean plasma RPV concentrations and data ranges after MAP (8mg) and IM (1.8 mg) administration of RPV in rats.
Time (Day) MAP mean plasma concentrations and ranges (ng/ml) n IM mean plasma concentrations and ranges (ng/ml) n
0 0.0 9 0.0 12
1 547.5 (85, 939.3) 9 175.5 (NQ, 555.8) 12
4 < LLOQ 6 (3 sample errors) 84.7 (NQ, 468.4) 11 (1 sample error)
7 430.7 (NQ, 1725.7) 9 <LLOQ (NQ) 11 (1 sample error)
28 75.6 (NQ, 208.7) 6 42.9 (NQ, 75.2) 8
56 104.4 (63.1, 162.6) 3 118.9 (70.4, 177.2) 4
Plasma concentrations below the lower limit of quantiﬁcation (LLOQ), or not quantiﬁable (NQ), were treated as 25 ng/ml in analyses (half the lower limit of
quantiﬁcation).
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[38]. The outcomes of that study are of particular importance and re-
levance as it was the ﬁrst study to investigate the self-application of
“large” MAPs. Moving toward patient usage, comprehensive skin irri-
tation and dermal toxicity evaluations must be carried out, followed by
user feasibility studies which will enhance MAP concept and design and
inform subsequent design approaches for these innovative drug delivery
devices.
4. Conclusions
This work documents a proof of principle study outlining the for-
mulation of novel dissolving MAPs for intradermal delivery of RPV.
This is the ﬁrst time that an ARV nanosuspension has been incorporated
into a MAP delivery format and the results illustrate the potential de-
livery capabilities of such a novel device. RPV LA administration via
MAP or IM led to comparable plasma, localised tissue and lymphoid
tissue distribution results. Moreover, it has been cautiously estimated
that an RPV LA MAP of approximately 28 cm2 could maintain ther-
apeutic plasma levels of RPV over 7 days in humans. This work supports
the potential future use of MAPs in the needle-free delivery of other
long-acting ARV drugs, thus eradicating the necessity for daily oral
medication regimens and eliminating the risks associated with needle-
stick injuries. The outcomes of the current study have now been utilized
to inform the target product proﬁle for ARV MAPs. Formulation opti-
misation, stability evaluations, comprehensive preclinical and clinical
pharmacokinetic studies, physiologically-based pharmacokinetic mod-
elling and patient usability/acceptability studies are now necessary to
fully realize the potential of these novel delivery platforms.
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